New insights on molecular mechanisms of renal aging

American Journal of Transplantation

Volumn 12, Issue 11, 2012, Pages 2892-2900

  Schmitt, R ^a   Melk, A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Donor age; kidney function; kidney graft survival; mitochondrial aging; renal transplantation; somatic cellular senescence

Indexed keywords

ARTICLE; CELL AGING; HUMAN; KIDNEY; KIDNEY TRANSPLANTATION; MITOCHONDRION; MOLECULAR MECHANICS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SOMATIC CELLULAR SENESCENCE;

AGING; ANIMALS; CELL AGING; FEMALE; GENETIC MARKERS; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MITOCHONDRIA; MOLECULAR BIOLOGY; SENSITIVITY AND SPECIFICITY; TISSUE DONORS;

EID: 84868209632     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04214.x     Document Type: Article

References (94)

1. Anderson S, Halter JB, Hazzard WR, et al,. Prediction, progression, and outcomes of chronic kidney disease in older adults. J Am Soc Nephrol 2009; 20: 1199-1209.
2. Ishani A, Xue JL, Himmelfarb J, et al,. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009; 20: 223-228.
3. Schmitt R, Coca S, Kanbay M, Tinetti ME, Cantley LG, Parikh CR,. Recovery of kidney function after acute kidney injury in the elderly: A systematic review and meta-analysis. Am J Kidney Dis 2008; 52: 262-271.
4. Chavalitdhamrong D, Gill J, Takemoto S, et al,. Patient and graft outcomes from deceased kidney donors age 70 years and older: An analysis of the Organ Procurement Transplant Network/United Network of Organ Sharing database. Transplantation 2008; 85: 1573-1579.
5. Frei U, Noeldeke J, Machold-Fabrizii V, et al,. Prospective age-matching in elderly kidney transplant recipients-A 5-year analysis of the Eurotransplant Senior Program. Am J Transplant 2008; 8: 50-57.
6. Naesens M, Lerut E, de Jonge H, Van Damme B, Vanrenterghem Y, Kuypers DR,. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol 2009; 20: 2468-2480.
7. Oberhuber R, Ge X, Tullius SG,. Donor age-specific injury and immune responses. Am J Transplant 2012; 12: 38-42.
8. Stallone G, Infante B, Gesualdo L,. Older donors and older recipients in kidney transplantation. J Nephrol 2010; 23 (Suppl 15): S98-103.
9. de Fijter JW,. An old virtue to improve senior programs. Transpl Int 2009; 22: 259-268.
10. Lindeman RD, Goldman R,. Anatomic and physiologic age changes in the kidney. Exp Gerontol 1986; 21: 379-406.
11. Gourtsoyiannis N, Prassopoulos P, Cavouras D, Pantelidis N,. The thickness of the renal parenchyma decreases with age: A CT study of 360 patients. AJR Am J Roentgenol 1990; 155: 541-544.
12. Melk A, Schmidt BM, Takeuchi O, Sawitzki B, Rayner DC, Halloran PF,. Expression of p16INK4a and other cell cycle regulator and senescence associated genes in aging human kidney. Kidney Int 2004; 65: 510-520.
13. Xue JL, Daniels F, Star RA, et al,. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol 2006; 17: 1135-1142.
14. Zhou XJ, Rakheja D, Yu X, Saxena R, Vaziri ND, Silva FG,. The aging kidney. Kidney Int 2008; 74: 710-720.
15. de Fijter JW, Mallat MJ, Doxiadis, II, et al,. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol 2001; 12: 1538-1546.
16. Yang H, Fogo AB,. Cell senescence in the aging kidney. J Am Soc Nephrol 2010; 21: 1436-1439.
17. Schmitt R, Marlier A, Cantley LG,. Zag expression during aging suppresses proliferation after kidney injury. J Am Soc Nephrol 2008; 19: 2375-2383.
18. Yang HC, Deleuze S, Zuo Y, Potthoff SA, Ma LJ, Fogo AB,. The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. J Am Soc Nephrol 2009; 20: 2380-2388.
19. Schmitt R, Cantley LG,. The impact of aging on kidney repair. Am J Physiol Renal Physiol 2008; 294: F1265-1272.
20. Melk A,. Senescence of renal cells: Molecular basis and clinical implications. Nephrol Dial Transplant 2003; 18: 2474-2478.
21. Perico N, Remuzzi G, Benigni A,. Aging and the kidney. Curr Opin Nephrol Hypertens 2011; 20: 312-317.
22. Melk A, Halloran PF,. Cell senescence and its implications for nephrology. J Am Soc Nephrol 2001; 12: 385-393.
23. Jacobi C, Homme M, Melk A,. Is cellular senescence important in pediatric kidney disease? Pediatr Nephrol 2011; 26: 2121-2131.
24. Wills LP, Schnellmann RG,. Telomeres and telomerase in renal health. J Am Soc Nephrol 2011; 22: 39-41.
25. Naesens M,. Replicative senescence in kidney aging, renal disease, and renal transplantation. Discov Med 2011; 11: 65-75.
26. Hayflick L, Moorhead PS,. The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 25: 585-621.
27. Varela E, Blasco MA,. 2009 nobel prize in physiology or medicine: Telomeres and telomerase. Oncogene 2010; 29: 1561-1565.
28. von Zglinicki T,. Oxidative stress shortens telomeres. Trends Biochem Sci 2002; 27: 339-344.
29. Chen JH, Stoeber K, Kingsbury S, Ozanne SE, Williams GH, Hales CN,. Loss of proliferative capacity and induction of senescence in oxidatively stressed human fibroblasts. J Biol Chem 2004; 279: 49439-49446.
30. Wright WE, Shay JW,. Telomere dynamics in cancer progression and prevention: Fundamental differences in human and mouse telomere biology. Nat Med 2000; 6: 849-851.
31. Wright WE, Shay JW,. Historical claims and current interpretations of replicative aging. Nat Biotechnol 2002; 20: 682-688.
32. Weinberg RA,. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
33. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA,. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996; 85: 27-37.
34. Ramirez RD, Morales CP, Herbert BS, et al,. Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. Genes Dev 2001; 15: 398-403.
35. Narita M, Krizhanovsky V, Nunez S, et al,. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 2006; 126: 503-514.
36. Beausejour CM, Krtolica A, Galimi F, et al,. Reversal of human cellular senescence: Roles of the p53 and p16 pathways. EMBO J 2003; 22: 4212-4222.
37. Kurz DJ, Decary S, Hong Y, Erusalimsky JD,. Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci 2000; 113 (Pt 20): 3613-3622.
38. Dimri GP, Lee X, Basile G, et al,. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995; 92: 9363-9367.
39. Itahana K, Campisi J, Dimri GP,. Methods to detect biomarkers of cellular senescence: The senescence-associated beta-galactosidase assay. Methods Mol Biol 2007; 371: 21-31.
40. Terman A, Gustafsson B, Brunk UT,. Autophagy, organelles and ageing. J Pathol 2007; 211: 134-143.
41. Campisi J,. Cellular senescence and apoptosis: How cellular responses might influence aging phenotypes. Exp Gerontol 2003; 38: 5-11.
42. Williams GC,. Pleiotropy, natural selection and the evolution of senescence. Evolution 1957; 11: 389-411.
43. Humphreys BD, Czerniak S, DiRocco DP, Hasnain W, Cheema R, Bonventre JV,. Repair of injured proximal tubule does not involve specialized progenitors. Proc Natl Acad Sci U S A 2011; 108: 9226-9231.
44. Nadasdy T, Laszik Z, Blick KE, Johnson LD, Silva FG,. Proliferative activity of intrinsic cell populations in the normal human kidney. J Am Soc Nephrol 1994; 4: 2032-2039.
45. Chkhotua AB, Gabusi E, Altimari A, et al,. Increased expression of p16(INK4a) and p27(Kip1) cyclin-dependent kinase inhibitor genes in aging human kidney and chronic allograft nephropathy. Am J Kidney Dis 2003; 41: 1303-1313.
46. Krishnamurthy J, Torrice C, Ramsey MR, et al,. Ink4a/Arf expression is a biomarker of aging. J Clin Invest 2004; 114: 1299-1307.
47. Melk A, Ramassar V, Helms LM, et al,. Telomere shortening in kidneys with age. J Am Soc Nephrol 2000; 11: 444-453.
48. Ferlicot S, Durrbach A, Ba N, Desvaux D, Bedossa P, Paradis V,. The role of replicative senescence in chronic allograft nephropathy. Hum Pathol 2003; 34: 924-928.
49. Westhoff JH, Schildhorn C, Jacobi C, et al,. Telomere shortening reduces regenerative capacity after acute kidney injury. J Am Soc Nephrol 2010; 21: 327-336.
50. Sis B, Tasanarong A, Khoshjou F, Dadras F, Solez K, Halloran PF,. Accelerated expression of senescence associated cell cycle inhibitor p16INK4A in kidneys with glomerular disease. Kidney Int 2007; 71: 218-226.
51. Melk A, Schmidt BM, Vongwiwatana A, Rayner DC, Halloran PF,. Increased expression of senescence-associated cell cycle inhibitor p16INK4a in deteriorating renal transplants and diseased native kidney. Am J Transplant 2005; 5: 1375-1382.
52. Chkhotua AB, Abendroth D, Froeba G, Schelzig H,. Up-regulation of cell cycle regulatory genes after renal ischemia/reperfusion: Differential expression of p16(INK4a), p21(WAF1/CIP1) and p27(Kip1) cyclin-dependent kinase inhibitor genes depending on reperfusion time. Transpl Int 2006; 19: 72-77.
53. Melk A, Schmidt BM, Braun H, et al,. Effects of donor age and cell senescence on kidney allograft survival. Am J Transplant 2009; 9: 114-123.
54. Koppelstaetter C, Schratzberger G, Perco P, et al,. Markers of cellular senescence in zero hour biopsies predict outcome in renal transplantation. Aging Cell 2008; 7: 491-497.
55. McGlynn LM, Stevenson K, Lamb K, et al,. Cellular senescence in pretransplant renal biopsies predicts postoperative organ function. Aging Cell 2009; 8: 45-51.
56. Michaloglou C, Vredeveld LC, Soengas MS, et al,. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436: 720-724.
57. Xue W, Zender L, Miething C, et al,. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 656-660.
58. Krizhanovsky V, Yon M, Dickins RA, et al,. Senescence of activated stellate cells limits liver fibrosis. Cell 2008; 134: 657-667.
59. Jennings P, Koppelstaetter C, Aydin S, et al,. Cyclosporine A induces senescence in renal tubular epithelial cells. Am J Physiol Renal Physiol 2007; 293: F831-838.
60. Furuzawa-Carballeda J, Lima G, Alberu J, et al,. Infiltrating cellular pattern in kidney graft biopsies translates into forkhead box protein 3 up-regulation and p16INK4alpha senescence protein down-regulation in patients treated with belatacept compared to cyclosporin A. Clin Exp Immunol 2012; 167: 330-337.
61. Hewitson TD,. Renal tubulointerstitial fibrosis: Common but never simple. Am J Physiol Renal Physiol 2009; 296: F1239-1244.
62. Liu D, Hornsby PJ,. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res 2007; 67: 3117-3126.
63. Pitiyage GN, Slijepcevic P, Gabrani A, et al,. Senescent mesenchymal cells accumulate in human fibrosis by a telomere-independent mechanism and ameliorate fibrosis through matrix metalloproteinases. J Pathol 2011; 223: 604-617.
64. Wolstein JM, Lee DH, Michaud J, Buot V, Stefanchik B, Plotkin MD,. INK4a knockout mice exhibit increased fibrosis under normal conditions and in response to unilateral ureteral obstruction. Am J Physiol Renal Physiol 2010; 299: F1486-1495.
65. Balaban RS, Nemoto S, Finkel T,. Mitochondria, oxidants, and aging. Cell 2005; 120: 483-495.
66. Kelly DP,. Cell biology: Ageing theories unified. Nature 2011; 470: 342-343.
67. Hall AM, Unwin RJ,. The not so 'mighty chondrion': Emergence of renal diseases due to mitochondrial dysfunction. Nephron Physiol 2007; 105: p1-10.
68. Sahin E, Colla S, Liesa M, et al,. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011; 470: 359-365.
69. Sugden MC, Caton PW, Holness MJ,. PPAR control: It's SIRTainly as easy as PGC. J Endocrinol 2010; 204: 93-104.
70. Herranz D, Munoz-Martin M, Canamero M, et al,. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun 2010; 1: 1-8.
71. He W, Wang Y, Zhang MZ, et al,. Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest 2010; 120: 1056-1068.
72. Coffman TM, Crowley SD,. Kidney in hypertension: Guyton redux. Hypertension 2008; 51: 811-816.
73. Ruster C, Wolf G,. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006; 17: 2985-2991.
74. Cassis P, Conti S, Remuzzi G, Benigni A,. Angiotensin receptors as determinants of life span. Pflugers Arch 2010; 459: 325-332.
75. Herbert KE, Mistry Y, Hastings R, Poolman T, Niklason L, Williams B,. Angiotensin II-mediated oxidative DNA damage accelerates cellular senescence in cultured human vascular smooth muscle cells via telomere-dependent and independent pathways. Circ Res 2008; 102: 201-208.
76. Gwathmey TM, Westwood BM, Pirro NT, et al,. Nuclear angiotensin-(1-7) receptor is functionally coupled to the formation of nitric oxide. Am J Physiol Renal Physiol 2010; 299: F983-990.
77. Cook JL, Zhang Z, Re RN,. In vitro evidence for an intracellular site of angiotensin action. Circ Res 2001; 89: 1138-1146.
78. Erdmann B, Fuxe K, Ganten D,. Subcellular localization of angiotensin II immunoreactivity in the rat cerebellar cortex. Hypertension 1996; 28: 818-824.
79. Abadir PM, Foster DB, Crow M, et al,. Identification and characterization of a functional mitochondrial angiotensin system. Proc Natl Acad Sci U S A 2011; 108: 14849-14854.
80. Costa LE, La-Padula P, Lores-Arnaiz S, et al,. Long-term angiotensin II inhibition increases mitochondrial nitric oxide synthase and not antioxidant enzyme activities in rat heart. J Hypertens 2002; 20: 2487-2494.
81. de Cavanagh EM, Piotrkowski B, Basso N, et al,. Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. FASEB J 2003; 17: 1096-1098.
82. Benigni A, Corna D, Zoja C, et al,. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 2009; 119: 524-530.
83. Ryan MT, Hoogenraad NJ,. Mitochondrial-nuclear communications. Annu Rev Biochem 2007; 76: 701-722.
84. Pergola PE, Raskin P, Toto RD, et al,. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011; 365: 327-336.
85. Imamura R, Isaka Y, Sandoval RM, et al,. Intravital two-photon microscopy assessment of renal protection efficacy of siRNA for p53 in experimental rat kidney transplantation models. Cell transplantation 2010; 19: 1659-1670.
86. Chkhotua AB, Schelzig H, Wiegand P, et al,. Influence of ischaemia/reperfusion and LFA-1 inhibition on telomere lengths and CDKI genes in ex vivo haemoperfusion of primate kidneys. Transplant Int 2005; 17: 692-698.
87. Schelzig H, Chkhotua AB, Wiegand P, et al,. Effect of ischemia/reperfusion on telomere length and CDKI genes expression in a concordant ex-vivo hemoperfusion model of primate kidneys. Ann Transplant 2003; 8: 17-21.
88. Joosten SA, van Ham V, Nolan CE, et al,. Telomere shortening and cellular senescence in a model of chronic renal allograft rejection. Am J Pathol 2003; 162: 1305-1312.
89. Baumann M, Bartholome R, Peutz-Kootstra CJ, Smits JF, Struijker-Boudier HA,. Sustained tubulo-interstitial protection in SHRs by transient losartan treatment: An effect of decelerated aging? Am J hypertens 2008; 21: 177-182.
90. Molitoris BA, Dagher PC, Sandoval RM, et al,. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 2009; 20: 1754-1764.
91. Kown MH, Murata S, Jahncke CL, et al,. Donor cardiac allografts from p53 knockout mice exhibit apoptosis-independent prolongation of survival. Transplant proceed 2002; 34: 3274-3276.
92. Hochegger K, Koppelstaetter C, Tagwerker A, et al,. p21 and mTERT are novel markers for determining different ischemic time periods in renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2007; 292: F762-768.
93. Lunz JG, 3rd, Contrucci S, Ruppert K, et al,. Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: Increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am J pathol 2001; 158: 1379-1390.
94. Westhoff JH, Hilgers KF, Steinbach MP, et al,. Hypertension induces somatic cellular senescence in rats and humans by induction of cell cycle inhibitor p16INK4a. Hypertension 2008; 52: 123-129.